- Overview:
- This study evaluates the safety and effectiveness of an inhaled short-acting insulin in children.
- Staus:
- Enrolling
- Clinical Description:
- This study is evaluating the efficacy and safety of Afrezza, an inhaled insulin, in combination with a basal insulin versus insulin aspart or insulin lispro in combination with a basal insulin in pediatric subjects with type 1 or type 2 diabetes mellitus.
- Target Age/Sex:
- Over 4 years and under 18, Male & Female (on multiple daily injections)
- Benefits:
- Participants will receive at no cost: study product, study materials and study-specific procedures.
- Study Length:
- About 56 Weeks
- Link:
- ClinicalTrials.gov
